Ads
related to: gastric cancer her2 positive- Biomarker Testing
See How Testing Reveals a Prevalent
Target for First-Line Treatment.
- Request a Rep
Request a Representative to Learn
More About This Treatment Option.
- Efficacy & Safety
View Response Data, Study Design,
& Safety Data for Phase 3 Trials.
- Dosing and Admin
View Recommended Dosing and
Administration Information.
- Biomarker Testing
Search results
Results from the WOW.Com Content Network
Trastuzumab deruxtecan is indicated for the treatment of adults with unresectable (unable to be removed with surgery) or metastatic (when cancer cells spread to other parts of the body) HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting and for adults with locally advanced or metastatic HER2-positive gastric or gastroesophageal ...
Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer. [30] [27] [31] [32] It is specifically used for cancer that is HER2 receptor positive. [30] It may be used by itself or together with other chemotherapy medication. [30]
HER2 is the target of the monoclonal antibody trastuzumab (marketed as Herceptin). Trastuzumab is effective only in cancers where HER2 is over-expressed. One year of trastuzumab therapy is recommended for all patients with HER2-positive breast cancer who are also receiving chemotherapy. [33] Twelve months of trastuzumab therapy is optimal.
In China, disitamab vedotin was approved in 2021 for the treatment of patients with HER2-overexpressing locally advanced or metastatic gastric cancer, including gastroesophageal junction adenocarcinoma, who have received at least two systemic chemotherapy regimens. [2]
It is licensed for the treatment of breast cancer or gastric or gastroesophageal adenocarcinoma. [2] Patritumab deruxtecan, an experimental antibody–drug conjugate to treat non-small-cell lung cancer. [3] [4] [5] Ifinatamab deruxtecan, an experimental anti-cancer treatment. [6] [7]
] The highest rate of stomach cancer was in Mongolia, at 28 cases per 100,000 people. [105] [unreliable source?] In the United Kingdom, stomach cancer is the 15th most-common cancer (around 7,100 people were diagnosed with stomach cancer in 2011), and it is the 10th most-common cause of cancer-related deaths (around 4,800 people died in 2012 ...
Margetuximab, sold under the brand name Margenza, is a chimeric IgG monoclonal antibody medication against HER2 used for the treatment of cancer. [3] [4]The most common adverse drug reactions in combination with chemotherapy are fatigue/asthenia, nausea, diarrhea, vomiting, constipation, headache, pyrexia, alopecia, abdominal pain, peripheral neuropathy, arthralgia/myalgia, cough, decreased ...
In the United States, trastuzumab emtansine was approved specifically for treatment of HER2-positive metastatic breast cancer (mBC) in patients who have been treated previously with trastuzumab and a taxane (paclitaxel or docetaxel), and who have already been treated for mBC or developed tumor recurrence within six months of adjuvant therapy.
Ads
related to: gastric cancer her2 positive